Allergan Announces Plans to Acquire Oculeve for $125 million + Milestones

| Printer friendly version

Allergan recently announced that it has agreed to buy Oculeve in an all-cash transaction.  The deal is expected to close in the third quarter of 2015.  Press releases state that Allergan will pay Oculeve $125 million upfront, and that  Allergan will also pay Oculeve additional commercial milestone payments that are related to Oculeve’s lead development project.

According to press releases, Oculeve is a development-stage medical device company focused on developing novel treatments for dry eye disease.  The press releases note that Oculeve was founded out of a collaboration with the Stanford Biodesign Center and Department of Ophthalmology at Stanford University. The press releases further state that Oculeve’s lead development project, OD-01, is a non-invasive nasal neurostimulation device that increases tear production in patients with chronic dry eye; Oculeve has already completed four clinical studies showing positive safety and efficacy of the product; Allergan plans to complete an additional two studies before submitting the product to the FDA; and that Allergan and Oculeve hope to commercially launch OD-01 in 2017.

According to its website, Allergan is a leading global pharmaceutical company with commercial operations in approximately 100 countries.  According to Allergan, the company is focused on developing branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Leave a Reply

By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.